Astria Therapeutics, Inc. (NASDAQ:ATXS) Stock Holdings Reduced by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC lessened its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,984 shares of the biotechnology company’s stock after selling 2,300 shares during the period. ADAR1 Capital Management LLC owned 0.16% of Astria Therapeutics worth $813,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in shares of Astria Therapeutics by 2.3% during the 4th quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock worth $556,000 after purchasing an additional 1,381 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Astria Therapeutics by 9.9% in the 4th quarter. American Century Companies Inc. now owns 42,693 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 3,839 shares during the period. New York State Common Retirement Fund raised its holdings in Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Astria Therapeutics in the fourth quarter valued at about $41,000. Finally, Intech Investment Management LLC raised its holdings in Astria Therapeutics by 31.2% during the 4th quarter. Intech Investment Management LLC now owns 27,104 shares of the biotechnology company’s stock worth $242,000 after buying an additional 6,439 shares during the period. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Down 9.5 %

ATXS stock opened at $4.66 on Monday. Astria Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $12.92. The firm has a market capitalization of $262.98 million, a PE ratio of -2.23 and a beta of 0.68. The stock has a 50-day simple moving average of $6.58 and a two-hundred day simple moving average of $8.91.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. On average, equities research analysts anticipate that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ATXS. Wedbush reissued an “outperform” rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. JMP Securities initiated coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Citizens Jmp upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $26.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.